Management of von Willebrand Disease in Developing Countries

 

 Buy Article Permissions and Reprints

ABSTRACT

A variety of treatment options are available at present for patients with von Willebrand disease (vWD), some of which are affordable for patients in developing countries. For most patients who have type 1 vWD, desmopressin acetate (DDAVP) is the treatment of first choice, at least for minor bleedings and for prophylaxis. It is advisable, however, to use a test dose first to note the patient’s response. DDAVP is safe to use, affordable, and easy to administer. However, most patients with type 2 vWD and all patients with type 3 fail to respond to DDAVP. For these patients, other options are used. Almost all patients with vWD will benefit from fresh frozen plasma and from cryoprecipitate, and these are viable options for developing countries. Both have certain disadvantages, but they can, depending upon the circumstances and facilities, be produced in developing countries. In developed countries, factor VIII/von Willebrand factor concentrates are widely used, especially for major bleedings and for surgeries on these patients. These concentrates are safe and virus inactivated, but costly. Ancillary treatment modalities such as antifibrinolytic agents and certain hormones are usually given in conjunction with other modalities. The treatment of patients with antibodies to vWF is also described, and monitoring needs during therapy are reviewed.

REFERENCES

• 1 Sadler J E, Mannucci P M, Berntorp E et al.. Impact, diagnosis and treatment of von Willebrand disease.  Thromb Haemost. 2000;  84 160-174
  Article in Thieme ConnectPubMedGoogle Scholar
• 2 Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease.  Blood. 1987;  69 454-459
  PubMedGoogle Scholar
• 3 Werner E J, Broxson E H, Tucker E L, Giroux D S, Shults J, Abshire T C. Prevalence of von Willebrand disease in children: a multiethnic study.  J Pediatr. 1993;  123 893-898
  CrossrefPubMedGoogle Scholar
• 4 Sadler J E. Biochemistry and genetics of von Willebrand factor.  Annu Rev Biochem. 1998;  67 395-424
  CrossrefPubMedGoogle Scholar
• 5 Kaufmann J E, Oksche A, Wollheim C B, Günther G, Rosenthal W, Vischer U M. Vasopressin induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP.  J Clin Invest. 2000;  106 107-116
  PubMedGoogle Scholar
• 6 Mannucci P M, Aberg M, Nilsson I M, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs.  Br J Haematol. 1975;  30 81-93
  CrossrefPubMedGoogle Scholar
• 7 Mannucci P M, Canciani M T, Rota L, Donovan B S. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand disease.  Br J Haematol. 1981;  47 283-293
  PubMedGoogle Scholar
• 8 Rodeghiero F, Castaman G, Mannucci P M. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A.  Thromb Haemost. 1996;  76 692-696
  PubMedGoogle Scholar
• 9 Mannucci P M, Ruggeri Z M, Pareti F I, Capitanio A M. Deamino-8-D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand disease.  Lancet. 1977;  1 869-872
  PubMedGoogle Scholar
• 10 Rodeghiero F, Castaman G, Di Bona E, Ruggeri M. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A.  Blood. 1989;  74 1997-2000
  PubMedGoogle Scholar
• 11 Mannucci P M, Lombardi R, Bader R et al.. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor.  Blood. 1985;  66 796-802
  PubMedGoogle Scholar
• 12 Ruggeri Z M, Mannucci P M, Lombardi R, Federici A B, Zimmerman T S. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand’s disease subtypes.  Blood. 1982;  59 1272-1278
  PubMedGoogle Scholar
• 13 Mazurier C, Gaucher C, Jorieux S, Goudemand M. Collaborative Group. . Biological effect of desmopressin in eight patients with type 2 N (‘Normandy’) von Willebrand disease.  Br J Haematol. 1994;  88 849-854
  PubMedGoogle Scholar
• 14 Mannucci P M, Lombardi R, Castaman G et al.. von Willebrand disease “Vicenza” with larger-than-normal (supranormal) von Willebrand factor multimers.  Blood. 1988;  71 65-70
  PubMedGoogle Scholar
• 15 Mannucci P M, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with hemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP).  Br J Haematol. 1992;  82 87-93
  CrossrefPubMedGoogle Scholar
• 16 Smith T J, Gill J C, Ambroso D R, Hathaway W E. Hyponatremia and seizures in young children given DDAVP.  Am J Hematol. 1989;  31 199-202
  CrossrefPubMedGoogle Scholar
• 17 Bond L, Bevin D. Myocardial infarction in a patient with hemophilia A treated with DDAVP.  N Engl J Med. 1988;  318 121 , (letter)
  PubMedGoogle Scholar
• 18 Byrnes J J, Larcada A, Moake J L. Thrombosis following desmopressin for uremic bleeding.  Am J Hematol. 1988;  28 63-65
  CrossrefPubMedGoogle Scholar
• 19 Horowitz B, Bonomo R, Prince A M, Chin S N, Brotman B, Shulman R W. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma.  Blood. 1992;  79 826-831
  PubMedGoogle Scholar
• 20 Perkins H A. Correction of the hemostatic defects in von Willebrand disease.  Blood. 1967;  30 375-380
  PubMedGoogle Scholar
• 21 Rodeghiero F, Castaman G, Meyer D, Mannucci P M. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease.  Vox Sang. 1992;  62 193-199
  PubMedGoogle Scholar
• 22 Dobrkovska A, Krzensk U, Chediak J R. Pharmacokinetics, efficacy and safety of Humate-P® in von Willebrand disease.  Haemophilia. 1998;  4 33-39
  PubMedGoogle Scholar
• 23 Lillicrap D, Poon M C, Walker I, Xie F, Schwartz B A. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.  Thromb Haemost. 2002;  87 224-230
  PubMedGoogle Scholar
• 24 Mannucci P M, Chediak J, Hanna W et al.. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study.  Blood. 2002;  99 450-456
  CrossrefPubMedGoogle Scholar
• 25 Kohler M, Hellstern P, Wenzel E. The use of heat-treated factor VIII concentrates in von Willebrand’s disease.  Blut. 1985;  50 25-27
  PubMedGoogle Scholar
• 26 Mazurier C, De Romeuf C, Parquet-Gernez A, Goudemand M. In vitro and in vivo characterization of a high-purity, solvent detergent treated factor VIII concentrate: evidence of its therapeutic efficacy in von Willebrand disease.  Eur J Haematol. 1989;  43 7-14
  PubMedGoogle Scholar
• 27 Pasi K J, William M D, Enayat M S, Hill F GH. Clinical and laboratory evaluation of the treatment of von Willebrand’s disease patients with heat treated factor VIII concentrate (BPL 8Y).  Br J Haematol. 1990;  75 228-233
  CrossrefPubMedGoogle Scholar
• 28 Lethagen S, Berntorp E, Nilsson I M. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand’s disease type III.  Ann Hematol. 1992;  65 253-259
  CrossrefPubMedGoogle Scholar
• 29 Hanna W T, Bona R D, Zimmerman C E, Carta C A, Hebert G Z, Rickles F R. The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease.  Thromb Haemost. 1994;  71 173-179
  PubMedGoogle Scholar
• 30 Goudemand J, Negrier C, Ounnoughene O, Sultan Y. Clinical management of patients with von Willebrand disease with a VHP VWF concentrate: the French experience.  Haemophilia. 1998;  4 48-53
  CrossrefPubMedGoogle Scholar
• 31 Mannucci P M. Hemostatic drugs.  N Engl J Med. 1998;  339 245-253
  PubMedGoogle Scholar
• 32 Ruggeri Z M, Mannucci P M, Bader R, Barbui T. Factor VIII-related properties in platelets from patients with von Willebrand’s disease.  J Lab Clin Med. 1978;  91 132-140
  PubMedGoogle Scholar
• 33 Castillo R, Monteagudo J, Escolar G, Ordinas A, Magallon M, Martin Villar J. Hemostatic effect of normal platelet transfusion in severe von Willebrand disease.  Blood. 1991;  77 1901-1905
  CrossrefPubMedGoogle Scholar
• 34 Mannucci P M, Meyer D, Ruggeri Z M, Koutts J, Ciavarella N, Lavergne J M. Precipitating antibodies in von Willebrand's disease.  Nature. 1976;  262 141-142
  CrossrefPubMedGoogle Scholar
• 35 Mannucci P M, Federici A B. Antibodies to von Willebrand factor in von Willebrand disease. In: Aledort LM, Hoyer LW, Lusher JM, et al Inhibitors to Coagulation Factors. New York; Plenum Press 1995: 87-92
  Google Scholar
• 36 Mannucci P M, Tamaro G, Narchi G et al.. Lifethreatening reaction to FVIII concentrate in a patient with severe vWD and alloantibodies to vWF.  Eur J Haematol. 1987;  39 467-470
  PubMedGoogle Scholar
• 37 Bergamaschini L, Mannucci P M, Federici A B, Coppola R, Guzzoni S, Agostoni A. Posttransfusion anaphylactic reaction in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor.  J Lab Clin Med. 1995;  125 348-355
  PubMedGoogle Scholar
• 38 Ciavarella N, Schiavoni M, Valenzano E et al.. Use of recombinant factor VIIa (NovoSeven) in the treatment of a patient with type III von Willebrand’s disease and an inhibitor against von Willebrand factor.  Haemostasis. 1996;  26(suppl 1) 150-154
  PubMedGoogle Scholar
• 39 Grossmann R E, Geisen U, Schwender S, Keller F. Continuous infusion of recombinant factor VIIa (NovoSeven) in the treatment of a patient with type III von Willebrand’s disease and alloantibodies against von Willebrand factor.  Thromb Haemost. 2000;  83 633-634
  PubMedGoogle Scholar
• 40 Boyer-Neumann C, Dreyfus M, Wolf M, Veyradier A, Meyer D. Multitherapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease.  J Thromb Haemost. 2003;  1 190-192
  CrossrefPubMedGoogle Scholar
• 41 Federici A B, Rand J H, Bucciarelli P et al.. Acquired von Willebrand syndrome: data from an international registry.  Thromb Haemost. 2000;  84 345-349 , (erratum Thromb Haemost 2000;  84 345-349
  PubMedGoogle Scholar
• 42 Federici A B, Stabile F, Castaman G, Canciani M T, Mannucci P M. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches.  Blood. 1998;  92 2707-2711
  PubMedGoogle Scholar
• 43 Pareti F I, Lattuada A, Bressi C et al.. Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis.  Circulation. 2000;  102 1290-1295
  CrossrefPubMedGoogle Scholar
• 44 Vincentelli A, Susen S, Le Tourneau T et al.. Acquired von Willebrand syndrome in aortic stenosis.  N Engl J Med. 2003;  349 343-349
  PubMedGoogle Scholar
• 45 Mannucci P M. Venous thromboembolism in von Willebrand disease.  Thromb Haemost. 2002;  88 378-379
  Article in Thieme ConnectPubMedGoogle Scholar
• 46 Makris M, Colvin B, Gupta V, Shields M L, Smith M P. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease.  Thromb Haemost. 2002;  88 387-388
  PubMedGoogle Scholar

Pier M MannucciM.D. 

University of Milan, Department of Medicine

Via Pace 9, 20122 Milano, Italy

Email: pmmannucci@libero.it